Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
163
datasets available to search
ShareScore release 0.9.0
Dataset results
163 results for “Pharmacotherapy”
Relapse prevention in panic disorder with pharmacotherapy: where are we now?
<p>Relapse prevention in panic disorder with pharmacotherapy: where are we now?</p> <p>ABSTRACT<br> Introduction: A substantial number of patients with PD experience relapse after the discontinuation<br> of effective pharmacotherapy, leading to detrimental effects on the individuals and considerable<br> societal costs. This suggests the need to optimize pharmacotherapy to minimize relapse risk.<br> Area covered: The present systematic review examines randomized, double-blind, placebo-controlled<br> relapse prevention studies published over the last 20 years involving recommended medications. The<br> authors aim to provide an overview of this topic and evaluate whether recent advances were achieved.<br> Only seven studies were included, providing limited results. One-year maintenance pharmacotherapy<br> with constant doses had protective effects against relapse in patients who had previously exhibited<br> satisfactory responses to the same medication at the same doses. The duration of maintenance treatment<br> did not influence relapse risk. No data were available concerning the use of lower doses or the predictors<br> of relapse.<br> Expert opinion: Relapse prevention in PD has received limited attention. Recent progress and conclusive<br> indications are lacking. Rethinking pharmacological research in PD may be productive.<br> Collecting a wide range of clinical and individual features/biomarkers in large-scale, multicenter longterm<br> naturalistic studies, and implementing recent technological innovations (e.g., electronic medical<br> records/‘big data’ platforms, wearable devices, and machine learning techniques) may help identify<br> reliable predictive models.</p>
Relapse prevention in panic disorder with pharmacotherapy: where are we now?
<p>Relapse prevention in panic disorder with pharmacotherapy: where are we now?</p> <p>Introduction: A substantial number of patients with PD experience relapse after the discontinuation<br> of effective pharmacotherapy, leading to detrimental effects on the individuals and considerable<br> societal costs. This suggests the need to optimize pharmacotherapy to minimize relapse risk.<br> Area covered: The present systematic review examines randomized, double-blind, placebo-controlled<br> relapse prevention studies published over the last 20 years involving recommended medications. The<br> authors aim to provide an overview of this topic and evaluate whether recent advances were achieved.<br> Only seven studies were included, providing limited results. One-year maintenance pharmacotherapy<br> with constant doses had protective effects against relapse in patients who had previously exhibited<br> satisfactory responses to the same medication at the same doses. The duration of maintenance treatment<br> did not influence relapse risk. No data were available concerning the use of lower doses or the predictors<br> of relapse.<br> Expert opinion: Relapse prevention in PD has received limited attention. Recent progress and conclusive<br> indications are lacking. Rethinking pharmacological research in PD may be productive.<br> Collecting a wide range of clinical and individual features/biomarkers in large-scale, multicenter longterm<br> naturalistic studies, and implementing recent technological innovations (e.g., electronic medical<br> records/‘big data’ platforms, wearable devices, and machine learning techniques) may help identify<br> reliable predictive models.</p>
Dataset related to article: "Functional recovery in hip fracture patients: the role of pharmacotherapy"
<p>We provide the raw data used for the following article:</p> <ul> <li>Gialanella B, Santoro R, Prometti P, Giordano A, Monguzzi V, Comini L, Olivares A, Grioni G.<br> <em>Functional recovery in hip fracture patients: the role of pharmacotherapy</em>.<br> "Aging Clin Exp Res." 2020 Jan;32(1):49-57.<br> doi: 10.1007/s40520-019-01175-w. Epub 2019 Mar 21. PMID: 30900212.</li> </ul> <p><strong>Background and aim: </strong>The aim of this prospective observational cohort study was to verify the relationship between number of drugs used and functional outcome in hip fracture patients undergoing rehabilitation.</p> <p><strong>Methods: </strong>This study was conducted on 139 patients with hip fracture who underwent a rehabilitation program. Efficiency rate in the Functional Independence Measure (FIM) and Berg Balance Scale (BBS), and length of stay (LOS) were the outcome measures.</p> <p><strong>Results: </strong>At the end of rehabilitation, 66.1% of patients showed an increase in number of drugs used, while 33.9% used the same or lower number of drugs than at admission. At the end of rehabilitation patients with increased pharmacotherapy took a higher total number of drug classes (p = 0.001), had longer LOS (p = 0.009) and lower Berg efficiency (p = 0.048) than patients with the same or lower pharmacotherapy. The number of drugs used at discharge was an independent determinant of LOS (beta = 0.19, p = 0.022) and FIM efficiency (beta = - 0.20, p = 0.025). Age was a determinant of LOS (beta = 0.17, p = 0.044) and BBS efficiency (beta = - 0.23, p = 0.009), while CIRS severity was a determinant of BBS efficiency only (beta = - 0.22, p = 0.016).</p> <p><strong>Discussion: </strong>Findings of study indicate that in hip fracture patients, the number of drugs prescribed at discharge is an important indicator of LOS and rehabilitation efficiency.</p> <p><strong>Conclusions: </strong>These findings can help the physician to better plan the rehabilitation of hip fracture patients who require polypharmacy.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.